- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02592577
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
This first time in human study is intended for men and women at least 18 years of age who have advanced lung cancer which has grown or returned after being treated. In particular, it is a study for subjects who have a blood test positive for HLA-A*02:01 and/or HLA-A*02:06 and a tumor test positive for MAGE A10 protein expression (protein or gene). This trial is a dose escalation trial that will evaluate 3 doses of transduced cells administered after a lymphodepleting chemotherapy regimen using a 3+3 dose escalation design .The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells.
When the MAGE A10ᶜ⁷⁹⁶T cells are available, subjects will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by the T cell infusion. The purpose of this study is to test the safety of genetically changed T cells and find out what effects, if any, they have in subjects with lung cancer. The study will evaluate three different cell dose levels in order to find out the target cell dose. Once the target cell dose is determined, additional subjects will be enrolled to further test the safety and effects at this cell dose.
Subjects will be seen frequently by the Study Physician right after receiving their T cells back and up to first 6 months. After that, subjects will be seen every three months. Subjects will be seen every 6 months by their Study Physician for the first 5 years after the T cell infusion. If the T cells are found in the blood at five years, then the subjects will continue to be seen once a year until the T cells are no longer found in the blood for a maximum of 15 years. If the T cells are no longer found in the blood at 5 years, then the subject will be contacted by the Study Physician for the next 10 years. Subjects who have a confirmed response or clinical benefit ≥4 weeks after the first T-cell infusion and whose tumor continues to express the appropriate antigen target may be eligible for a second infusion. All subjects, completing or withdrawing from the Interventional Phase of the study, will enter a 15-year long-term follow-up phase for observation of delayed adverse events. All subjects will continue to be followed for overall survival during the long-term follow-up phase.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X6
- Princess Margaret Cancer Centre
-
-
-
-
-
Madrid, Spain, 28040
- Hospital Universitario Fundacion Jimenez Diaz
-
Madrid, Spain, 28041
- Hospital Universitario 12 Octubre Avda. de Córdoba s/n
-
-
-
-
-
London, United Kingdom, WC1E 6AG
- University College Hospital Macmillan Cancer Centre
-
Manchester, United Kingdom, M20 4BX
- The Christie Nhs Foundation Trust
-
-
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
Palo Alto, California, United States, 94304
- Stanford Cancer Center
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Sylvester Comprehensive Cancer Center
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Winship Cancer Institute of Emory University
-
-
Indiana
-
Indianapolis, Indiana, United States, 46033
- Indiana University Simon Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21157
- University of Maryland, Greenebaum Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University, School of Medicine
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center, Duke Cancer Institute
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology- Sarah Cannon Research Institute
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Md Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Subject has histologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or IV) or recurrent disease
- Subject has received at least one line of prior therapy
- Subjects with known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase receptor (ALK) or ROS1 gene rearrangements must have failed (progressive disease or unacceptable toxicity) at least one prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively. Subject may have received PD-1 or PDL-1 inhibitors and or chemotherapy. There is no limit on lines of prior anti-cancer therapy (a washout period applies for recent anti-cancer treatments).
- Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion.
- Subject is HLA-A*02:01 or HLA-A*02:06 positive.
- Subject's tumor (either an archival specimen or a fresh biopsy if archival tissue is unavailable) has been pathologically reviewed by a designated central laboratory confirming MAGE-A10 expression.
- Subject has an ECOG Performance Status 0-1 and anticipated life expectancy >6 months prior to apheresis and >3 months prior to lymphodepletion.
- Subject is ≥18 to ≤75 years of age
- Adequate organ function
Key Exclusion Criteria:
- Subject is HLA-A*02:05, HLA-B*15:01 and/or HLA-B*46:01 positive.
- History of chronic or recurrent (within the last year prior to enrollment) severe autoimmune or active immune-mediated disease requiring steroids or other immunosuppressive treatments.
- Subject has symptomatic CNS metastases. Subjects with prior history of symptomatic CNS metastasis must have received treatment and be neurologically stable for at least 1 month prior to leukapheresis and lymphodepletion.
- Active malignancy besides NSCLC within 3 years prior to screening.
Uncontrolled intercurrent illness including, but not limited to:
- Ongoing or active infection;
- Clinically significant cardiac disease
- Inadequate pulmonary function
- Interstitial lung disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with dose-limiting toxicity (DLT) and adverse events (AE), including serious adverse events (SAE)
Time Frame: 24 months
|
Determine if treatment with autologous genetically modified T cells, (MAGE A10ᶜ⁷⁹⁶T ) is safe and tolerable through assessment of DLTs, AEs, including SAEs; laboratory assessments, including chemistry, hematology, and coagulation; cardiac and pulmonary assessments, including ECG and troponin.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with a confirmed Complete Response (CR) or Partial Response (PR)
Time Frame: 24 months
|
Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1
|
24 months
|
Interval between the date of first T cell infusion dose and first documented evidence of CR or PR
Time Frame: 24 months
|
Evaluation of the efficacy of the treatment by assessment of time to first response
|
24 months
|
Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause
Time Frame: 24 months
|
Evaluation of the efficacy of the treatment by assessment of duration of response
|
24 months
|
Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause
Time Frame: 24 months
|
Evaluation of the efficacy of the treatment by assessment of duration of stable disease
|
24 months
|
Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause
Time Frame: 24 months
|
Evaluation of the efficacy of the treatment by assessment of progression-free survival
|
24 months
|
Interval between the date of first T cell infusion and date of disease progression or death due to any cause
Time Frame: 24 months
|
Evaluation of the efficacy of the treatment by assessment of overall survival
|
24 months
|
Best Overall Response (BOR)
Time Frame: 24 months
|
Best Overall Response (BOR), defined as the best response recorded from the date of T cell infusion until disease progression
|
24 months
|
To evaluate potential gene therapy-related delayed adverse events for 15 years post infusion.
Time Frame: 15 years
|
Presence of any of the following LTFU AEs:
|
15 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ben Creelan, MD, MS, H. Lee Moffitt Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADP 0022-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterEmbr Labs, Inc.Active, not recruitingHot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In SituUnited States
-
Institut BergoniéCompletedIntraductal Carcinoma and Lobular Carcinoma in SituFrance
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditionsUnited States
Clinical Trials on Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
-
AdaptimmuneActive, not recruitingHepatocellular Cancer | AFP Expressing TumorsUnited States, United Kingdom, France, Spain
-
AdaptimmuneTerminated
-
AdaptimmuneCompletedMelanoma | Head and Neck Cancer | Urothelial Carcinoma | Bladder Urothelial CarcinomaUnited States, Canada, Spain
-
AdaptimmuneActive, not recruitingMelanoma | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Urinary Bladder Cancer | Synovial Sarcoma | Gastroesophageal Junction | Myxoid Round Cell LiposarcomaUnited States, Canada
-
GlaxoSmithKlineCompleted
-
University of CologneUnknownCD30 Positive Cutaneous T Cell Lymphoma | CD30 Positive Transformed Mycosis FungoidesGermany
-
Tessa TherapeuticsActive, not recruitingAnaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)United States
-
University of PennsylvaniaCompleted
-
VIRxSYS CorporationActive, not recruiting